A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness

Vaccine

Volumn 29, Issue 10, 2011, Pages 1921-1928

  Langley, J M ^a,g   Aoki, F ^b   Ward, B J ^c   McGeer, A ^d   Angel, J B ^e   Stiver, G ^f   Gorfinkel, I ^g   Shu, D ^h   White, L ⁱ   Lasko, B ^j   Dzongowski, P ^k   Papp, K ^l   Alexander, M ^m   Boivin, G ⁿ   Fries, L ^o  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^f VANCOUVER GENERAL HOSPITAL   (Canada)

^g PrimeHealth Clinical Research   (Canada)

^h Gain Medical Center   (Canada)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

^j Manna Research   (Canada)

^k London East Medical Centre   (Canada)

^l PROBITY MEDICAL RESEARCH   (Canada)

^m Alexander Medical Innovations ^*  (Canada)

ⁿ LAVAL UNIVERSITY   (Canada)

^o GLAXOSMITHKLINE   (United States)

more..

Author keywords

Human; Influenza; Intranasal vaccine; Randomized controlled trial

Indexed keywords

DIPHENHYDRAMINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; OUTER MEMBRANE PROTEIN; PLACEBO; SECRETORY IMMUNOGLOBULIN; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BLURRED VISION; CHILL; COUGHING; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEART PALPITATION; HUMAN; HYPOTENSION; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION RISK; INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A H3N2; MALE; MUCOSAL IMMUNITY; MYALGIA; NASAL PRURITUS; NORMAL HUMAN; NOSE CONGESTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; RISK REDUCTION; SEASONAL INFLUENZA; SORE THROAT; TACHYCARDIA; VIRUS CULTURE; VIRUS IMMUNITY; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; BACTERIAL OUTER MEMBRANE PROTEINS; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A, SECRETORY; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEISSERIA MENINGITIDIS; PLACEBOS; SALIVA; TIME FACTORS; VACCINATION; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 79951726253     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.100     Document Type: Article

References (14)

1. Fiore A.E., Shay D.K., Haber P., Iskander J.K., Uyeki T.M., Mootrey G., et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep 2007, 56(RR-6):1-54.
2. Jefferson T.O., Rivetti D., Di Pietrantonj C., Rivetti A., Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007, (2):CD001269.
3. Eyles J., Williamson D., Alpar H. Intranasal administration of influenza vaccines current status. BioDrugs 2000, 13(1):35-59.
4. Langley J.M., Halperin S.A., McNeil S., Smith B., Jones T., Burt D., et al. Safety and immunogenicity of a proteosome-trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine 2006, 24(10):1601-1608.
5. Fries L., Lambkin R., Gelder Cea. FlulNsure and inactivated trivalent influenza vaccine for intranasal administration is protective in human challenge with A/Panama/2007/99 (H3N2). Options for the Control of Influenza V 2003.
6. An advisory committee statement (ACS). National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2003-2004 season. Can Commun Dis Rep 2003;29:1-20.
7. Boivin G., Cote S., Dery P., De Serres G., Bergeron M.G. Multiplex real-time PCR assay for detection of influenza and human respiratory syncytial viruses. J Clin Microbiol 2004, 42(1):45-51.
8. Ellis J.S., Fleming D.M., Zambon M.C. Multiplex reverse transcription-PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996. J Clin Microbiol 1997, 35(8):2076-2082.
9. Influenza in Canada: 2003-2004 season. Can Commun Dis Rep 2005;31(1):1-18.
10. Call S.A., Vollenweider M.A., Hornung C.A., Simel D.L., McKinney W.P. Does this patient have influenza? JAMA 2005, 293(8):987-997.
11. Treanor J., Nolan C., O'Brien D., Burt D., Lowell G., Linden J., et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 2006, 24(3):254-262.
12. Ribner B.S., Hall C., Steinberg J.P., Bernstein W.A., Chakkalakal R., Emamifar A., et al. Use of a mandatory declination form in a program for influenza vaccination of healthcare workers. Infect Control Hosp Epidemiol 2008, 29(4):302-308.
13. Deacon B., Abramowitz J. Fear of needles and vasovagal reactions among phlebotomy patients. J Anxiety Disord 2006, 20(7):946-960.
14. Atmar R.L., Keitel W.A., Cate T.R., Munoz F.M., Ruben F., Couch R.B. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine 2007, 25(29):5367-5373.